NewAmsterdam Pharma Co NV Sustainability Reports
NewAmsterdam Pharma Company N.V. is a late-stage clinical biopharmaceutical company focused on the research and development of transformative therapies for cardiometabolic diseases. Its primary asset under investigation is obicetrapib, an oral, low-dose, once-daily CETP inhibitor intended for patients with high-risk cardiovascular disease.
Sector: Manufacturing
Country: Netherlands
Exchange: Nasdaq
LEI: 984500B6549TF6E14D36
FIGI: BBG01BNNTQP2
2 reports from 2023 to 2024
